Renaissance International IPO ETF IPOS 深 滬
等待開盤 09-27 09:30:00 美东时间
17.1531
-0.212
-1.22%
華盛通- 最 高17.33
- 今 開17.33
- 成交量 2029股
- 最 低 17.1099
- 昨 收 17.365
- 總市值 514.59万
- 52周最高 17.81
- 市盈率 靜 --
- 換手率 0.68%
- 52周最低 10.671
- 委 比 0.00%
- 總股本 30.00万
- 歷史最高 40.6682
- 量 比 0.59
- 振 幅 1.27%
- 歷史最低 10.671
- 每 手 1
- 風險率 0.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Moleculin Biotech Secures Canadian Patent Titled "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE"
Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance f
09-25 20:40
ESGL Holdings Files Patent In Singapore For Technology Converting Hydrofluoric Acid Waste iInto Metallurgical-Grade Fluorspar
ESGL Holdings Limited (NASDAQ:ESGL), a leading carbon neutral, innovative enviro-tech company regenerating industrial waste into circular products, through its subsidiary Environmental Solutions Asia Pte Ltd
09-02 20:37
高盛：给予科伦博泰生物-B“买入”评级 目标价为239.14港元
高盛发布研报称，对科伦博泰生物-B（06990）给予“买入”评级，基于风险调整后的现金流折现（DCF）方法得出的12个月目标价为239.14港元，假设条件为...
03-14 11:26
降低脑转移机率 强生(JNJ.US)重磅疗法再获批准
新闻稿指出，与仅使用化疗相比，amivantamab与化疗联合疗法是在该患者群体中显示出无进展生存期(PFS)显著改善的首个治疗方案。 智通财经APP获悉...
2024-08-28 07:58
康方生物(9926.HK)专家解读：看好依沃西海外成功率 安全性或成关键优势；重申买入
公司近期召开投资者见面会，并邀请III 期HARMONi-A 试验（依沃西治疗EGFR-TKI 耐药NSCLC）的主要研究者作进一步解读，我们总结要点如下： 海...
2024-07-04 19:42
BitLayer生态项目盘点：新兴BitcoinLayer2存在着哪些机会？
文章转载来源： Eureka Partners Bitcoin Layer2 的展望 比特币最初被构想应用于电子支付系统，因此为了安全性和稳定性，非图灵完备的脚...
2024-05-11 09:39
Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023
AUDUBON, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, In...
2023-09-27 07:00
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting In Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival For RYBREVANT
https://www.jnj.com/phase-3-mariposa-2-study-meets-dual-primary-endpoint-resulting-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-for-rybrevant-amivantamab-vmjw-plus-chemo
2023-09-06 20:57
Healthcare Software Firm Waystar Goes IPO Way With Potential $8B Valuation
Waystar Inc, a provider of financial management software for hospitals and medical practices, is reportedly making strides toward an initial public offering (IPO) that could value the company up to $8 billion.
2023-08-22 21:24
Second Time Charm: Sagimet Biosciences Seeks Public Debut With $75M IPO
On Friday, Sagimet Biosciences, a clinical-stage biopharmaceutical company, filed with the SEC to raise up to $75 million in an initial public off
2023-06-27 00:47
